The role of mTOR in memory CD8+ T‐cell differentiation

Summary:  The mammalian target of rapamycin (mTOR) is an intracellular kinase that regulates cell growth and metabolism. Its specific inhibitor rapamycin is currently used in transplant recipients as an immunosuppressive drug to prevent allograft rejection. Studies have shown complex and diverse mechanisms for the immunosuppressive effects of rapamycin. The drug has been reported to inhibit T‐cell proliferation, induce anergy, modulate T‐cell trafficking, promote regulatory T cells, and also prevent maturation of dendritic cells as well as production of type I interferon. However, several other studies have paradoxically demonstrated immunostimulatory effects of rapamycin by improving antigen presentation and regulating cytokine production from macrophages and myeloid dendritic cells. Recently, it has been shown that rapamycin also exhibits immunostimulatory effects on memory CD8+ T‐cell differentiation. The drug improved both quantity and quality of memory CD8+ T cells induced by viral infection and vaccination, showing that mTOR is a major regulator of memory CD8+ T‐cell differentiation. These discoveries have implications for the development of novel vaccine regimens. Here, we review the role of mTOR in memory CD8+ T‐cell differentiation and compare the effect of rapamycin among CD8+ T cells, CD4+ T cells, and dendritic cells. Also, we discuss potential application of these findings in a clinical setting.

[1]  R. Marcén,et al.  Immunosuppressive Drugs in Kidney Transplantation , 2009, Drugs.

[2]  E. Meffre,et al.  Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. , 2009, Immunity.

[3]  S. Nutt,et al.  Blimp-1 transcription factor is required for the differentiation of effector CD8(+) T cells and memory responses. , 2009, Immunity.

[4]  E. Wherry,et al.  A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. , 2009, Immunity.

[5]  Russell G. Jones,et al.  Enhancing CD8 T-cell memory by modulating fatty acid metabolism , 2009, Nature.

[6]  P. Worley,et al.  The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. , 2009, Immunity.

[7]  R. Ahmed,et al.  mTOR regulates memory CD8 T cell differentiation , 2009, Nature.

[8]  A. Thomson,et al.  Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[9]  R. Hunter,et al.  Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells , 2009, Nature Medicine.

[10]  D. Masopust.  Developing an HIV cytotoxic T‐lymphocyte vaccine: issues of CD8 T‐cell quantity, quality and location , 2009, Journal of internal medicine.

[11]  K. Stuhlmeier,et al.  The TSC-mTOR signaling pathway regulates the innate inflammatory response. , 2008, Immunity.

[12]  B. Pulendran,et al.  Toll-like receptor–mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway , 2008, Nature Immunology.

[13]  T. Schulz,et al.  Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. , 2008, Transplantation.

[14]  S. Matsuda,et al.  Mammalian target of rapamycin and glycogen synthase kinase 3 differentially regulate lipopolysaccharide-induced interleukin-12 production in dendritic cells. , 2008, Blood.

[15]  L. Lefrançois,et al.  Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. , 2008, Immunity.

[16]  David K. Finlay,et al.  T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR , 2008, Proceedings of the National Academy of Sciences.

[17]  M. Blum,et al.  Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. , 2008, Transplantation proceedings.

[18]  J. Altman,et al.  Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. , 2008, Immunity.

[19]  David K. Finlay,et al.  Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking , 2008, Nature Immunology.

[20]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[21]  C. Benoist,et al.  The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells , 2008, The Journal of experimental medicine.

[22]  L. Hilbrands,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2008, The New England journal of medicine.

[23]  Antonio Polley,et al.  Strength of Stimulus and Clonal Competition Impact the Rate of Memory CD8 T Cell Differentiation12 , 2007, The Journal of Immunology.

[24]  T. Malek,et al.  Non‐redundant role for IL‐7R signaling for the survival of CD8+ memory T cells , 2007, European journal of immunology.

[25]  E. Wherry,et al.  Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. , 2007, Immunity.

[26]  E. Wherry,et al.  Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells , 2007, The Journal of experimental medicine.

[27]  Nikhil S. Joshi,et al.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. , 2007, Immunity.

[28]  K. Guan,et al.  Expanding mTOR signaling , 2007, Cell Research.

[29]  David M Sabatini,et al.  Defining the role of mTOR in cancer. , 2007, Cancer cell.

[30]  B. Guy,et al.  The perfect mix: recent progress in adjuvant research , 2007, Nature Reviews Microbiology.

[31]  S. Gruber,et al.  Sirolimus exposure during the early post‐transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients , 2007, Clinical transplantation.

[32]  A. Mondino,et al.  mTOR at the crossroads of T cell proliferation and tolerance. , 2007, Seminars in immunology.

[33]  Zhiliang Wang,et al.  Rapamycin-Conditioned Dendritic Cells Are Poor Stimulators of Allogeneic CD4+ T Cells, but Enrich for Antigen-Specific Foxp3+ T Regulatory Cells and Promote Organ Transplant Tolerance1 , 2007, The Journal of Immunology.

[34]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[35]  V. Kuchroo,et al.  Contrasting Effects of Cyclosporine and Rapamycin in De Novo Generation of Alloantigen‐Specific Regulatory T Cells , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[36]  M. Goldsmith,et al.  Impaired CD8 T cell memory and CD4 T cell primary responses in IL-7Rα mutant mice , 2007, The Journal of experimental medicine.

[37]  W. Haining,et al.  Resolution of a chronic viral infection after interleukin-10 receptor blockade , 2006, The Journal of experimental medicine.

[38]  J. Avruch,et al.  Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase , 2006, Oncogene.

[39]  N. Sonenberg,et al.  mTOR, translation initiation and cancer , 2006, Oncogene.

[40]  M. Tolaini,et al.  Do CD8 effector cells need IL-7R expression to become resting memory cells? , 2006, Blood.

[41]  Shimon Sakaguchi,et al.  Foxp3+CD25+CD4+ natural regulatory T cells in dominant self‐tolerance and autoimmune disease , 2006, Immunological reviews.

[42]  D. Valmori,et al.  Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells1 , 2006, The Journal of Immunology.

[43]  C. Klebanoff,et al.  CD8+ T‐cell memory in tumor immunology and immunotherapy , 2006, Immunological reviews.

[44]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[45]  Bali Pulendran,et al.  Translating Innate Immunity into Immunological Memory: Implications for Vaccine Development , 2006, Cell.

[46]  M. Hall,et al.  TOR Signaling in Growth and Metabolism , 2006, Cell.

[47]  Shizuo Akira,et al.  Innate immune recognition of viral infection , 2006, Nature Immunology.

[48]  E. Wherry,et al.  Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin , 2005, Nature Immunology.

[49]  J. Sprent,et al.  Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection , 2005, The Journal of experimental medicine.

[50]  M. Colonna,et al.  Plasmacytoid dendritic cells--virus experts of innate immunity. , 2005, Seminars in immunology.

[51]  M. Battaglia,et al.  Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. , 2005, Blood.

[52]  D. Alessi,et al.  Regulation of Akt/PKB Ser473 phosphorylation. , 2005, Molecular cell.

[53]  J. Curtsinger,et al.  Cutting Edge: Type I IFNs Provide a Third Signal to CD8 T Cells to Stimulate Clonal Expansion and Differentiation1 , 2005, The Journal of Immunology.

[54]  H. Robinson,et al.  T cell vaccines for microbial infections , 2005, Nature Medicine.

[55]  A. Rudensky,et al.  A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3 , 2005, Nature Immunology.

[56]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[57]  M. Bevan.  Helping the CD8+ T-cell response , 2004, Nature Reviews Immunology.

[58]  Hermann Wagner,et al.  Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[59]  K. Schwarz,et al.  Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects , 2004, The Journal of Immunology.

[60]  D. Hafler,et al.  Rapamycin-resistant Proliferation of CD8+ T Cells Correlates with p27kip1 Down-regulation and bcl-xL Induction, and Is Prevented by an Inhibitor of Phosphoinositide 3-Kinase Activity* , 2004, Journal of Biological Chemistry.

[61]  E. Wherry,et al.  Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells , 2003, Nature Immunology.

[62]  A. Thomson,et al.  Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. , 2003, Blood.

[63]  Rustom Antia,et al.  Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.

[64]  E. Wherry,et al.  Interleukin 15 Is Required for Proliferative Renewal of Virus-specific Memory CD8 T Cells , 2002, The Journal of experimental medicine.

[65]  Rustom Antia,et al.  Estimating the Precursor Frequency of Naive Antigen-specific CD8 T Cells , 2002, The Journal of experimental medicine.

[66]  Dirk Homann,et al.  Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory , 2001, Nature Medicine.

[67]  D. Hafler,et al.  Uncoupling p70s6 Kinase Activation and Proliferation: Rapamycin-Resistant Proliferation of Human CD8+ T Lymphocytes1 , 2001, The Journal of Immunology.

[68]  J. Altman,et al.  Cutting Edge: Increased Expression of Bcl-2 in Antigen-Specific Memory CD8+ T Cells1 , 2000, The Journal of Immunology.

[69]  J. Altman,et al.  Persistence of memory CD8 T cells in MHC class I-deficient mice. , 1999, Science.

[70]  J. Altman,et al.  Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.

[71]  David Gray,et al.  Immunological Memory and Protective Immunity: Understanding Their Relation , 1996, Science.

[72]  V. Berlin,et al.  RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[73]  Paul Tempst,et al.  RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs , 1994, Cell.

[74]  Stuart L. Schreiber,et al.  A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.

[75]  R. Ahmed,et al.  Cytotoxic T-cell memory without antigen , 1994, Nature.

[76]  J. Heitman,et al.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast , 1991, Science.

[77]  N. Sonenberg,et al.  Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy , 2012, BioDrugs.

[78]  G. Galbraith.  Changes in the Immune Responses Against Human Herpesvirus-8 in the Disease Course of Posttransplant Kaposi Sarcoma , 2010 .

[79]  R. Steinman,et al.  Dendritic cells: translating innate to adaptive immunity. , 2006, Current topics in microbiology and immunology.